Close Menu

NEW YORK – Centogene on Tuesday increased its revenue guidance for 2020 by about 30 percent as its core business is recovering and its COVID-19 testing is booming. In a separate announcement, the firm said that its CEO is stepping down.

The Rostock, Germany-based rare disease diagnostics and research company said it is increasing its full-year revenue guidance by 23 percent to 33 percent. The company now expects more than €80 million ($94.5 million) in 2020 revenues, up from an earlier estimate of between €60 million and €65 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.